Prolonged usage of B6 and overdose can lead to CNS adverse effects, including ataxia
Obesity indication approval expanded GLP-1 addressable market by an estimated 10-15: The US obesity drug market was approximately USD 2 billion in 2021 before Wegovy's approval
Safety outcomes encompassed treatment-emergent and serious adverse events, the presence of anti-cagrilintide antibodies, and changes in blood pressure, pulse rate, high-sensitivity C-reactive protein, plasma renin activity, and aldosterone levels
This is usually not serious
GHK-Cu
Theres been no groundswell from our members about challenging these items, perhaps because they dont meet the criteria under 503A. Under Section 503A of the Food, Drug & Cosmetic Act, an eligible bulk drug substance for compounding must be a component of an FDA-approved drug, must have a USP or NF monograph, or must appear on FDAs 503A Bulks List or Interim Bulks List Category 1